Frontiers in Pharmacology (Nov 2016)

miR-150 suppresses the proliferation and tumorigenicity of leukemia stem cells by targeting the Nanog signaling pathway

  • Dan-dan Xu,
  • Dan-dan Xu,
  • Peng-jun Zhou,
  • Peng-jun Zhou,
  • Ying Wang,
  • Ying Wang,
  • Yi Zhang,
  • Rong Zhang,
  • Li Zhang,
  • Su-hong Chen,
  • Bi-bo Ruan,
  • Hai-peng Xu,
  • Wu-yu Fu,
  • Chao-zhi Hu,
  • Lu Tian,
  • Jin-hong Qin,
  • Sheng Wang,
  • Xiao Wang,
  • Qiu-ying Liu,
  • Zhe Ren,
  • Xue-qui Gu,
  • Yao-he Li,
  • Zhong Liu,
  • Yi Fei Wang

DOI
https://doi.org/10.3389/fphar.2016.00439
Journal volume & issue
Vol. 7

Abstract

Read online

Proliferation, a key feature of cancer cells, accounts for the majority of cancer-related diseases resulting in mortality. MicroRNAs (miRNAs) plays important post-transcriptional modulation roles by acting on multiple signaling pathways, but the underlying mechanism in proliferation and tumorigenicity is unclear. Here, we identified the role of miR-150 in proliferation and tumorigenicity in leukemia stem cells (LSCs) (CD34+CD38- cells). miR-150 expression was significantly down-regulated in LSCs from leukemia cell lines and clinical samples. Functional assays demonstrated that increased miR-150 expression inhibited proliferation and clonal and clonogenic growth, enhanced chemosensitivity, and attenuated tumorigenic activity of LSCs in vitro. Transplantation animal studies revealed that miR-150 overexpression progressively abrogates tumour growth. Immunohistochemistry assays demonstrated that miR-150 overexpression enhanced caspase-3 level and reduced Ki-67 level. Moreover, luciferase reporter assays indicated Nanog is a direct and functional target of miR-150. Nanog silencing using small interfering RNA recapitulated anti-proliferation and tumorigenicity inhibition effects. Furthermore, miR-150 directly down-regulated the expression of other cancer stem cell factors including Notch2 and CTNNB1. These results provide insights into the specific biological behaviour of miR-150 in regulating LSC proliferation and tumorigenicity. Targeting this miR-150/Nanog axis would be a helpful therapeutic strategy to treat acute myeloid leukemia.

Keywords